Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Acquires Automation Firm, Inks Microfluidics Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex today announced that it has acquired robotics and automation firm BSD Robotics and has inked an exclusive collaboration with a digital microfluidics firm.

The Austin, Texas-based firm celebrated the 10th anniversary of its Nasdaq listing by ringing the opening bell of the market and then held its Annual Investors Day. It announced the acquisition and alliance at that meeting.

Luminex said that the acquisition of BSD Robotics will provide it with new technologies in automation and robotics in the field of dry sample handling. The privately held Australian firm operates in several markets including newborn screening, forensics and human identification, and molecular diagnostics.

The firms did not disclose the acquisition price.

Luminex also announced an exclusive licensing agreement with Advanced Liquid Logic, under which the firms intend to co-develop new analytic systems and assays "that will help clinicians and scientists across several strategic markets deliver highly accurate results faster and more efficiently."

ALL was founded in 2004 to develop digital microfluidics technology from Duke University. The Morrisville, NC-based firm's technology enables liquid handling without pipes, pumps, or valves, with droplets being electrically manipulated. Luminex said that the digital microfluidics could be combined with its xMAP technology and three-dimensional liquid arrays to form a "very versatile sample preparation and assay development platform."

"By combining Liquid Logic's digital microfluidic technology with Luminex's xMAP technology, we can create smaller, more cost-efficient systems and very streamlined assays that require less hands-on time and provide very fast, accurate results," Advanced Liquid Logic CEO Richard West said in a statement.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.